踝臂指数筛查外周动脉疾病的证据报告与系统综述
该系统综述为美国预防服务工作组更新证据,纳入5项研究(共5864名参与者),评估踝臂指数(ABI)筛查外周动脉疾病(PAD)的诊断准确性及治疗获益与危害。结果显示,无直接证据支持筛查获益;单一诊断准确性研究显示ABI敏感性低(7%-34%)、特异性高(96%-100%),阿司匹林治疗对复合心血管结局无显著影响,运动试验未改善生活质量或步行距离。
要点
- 无直接证据表明ABI筛查可改善无症状人群的健康结局。
- ABI筛查诊断敏感性低(7%-34%),特异性高(96%-100%)。
- 阿司匹林对筛查发现的无症状PAD患者复合心血管结局无显著获益。
核心结论
- 无直接证据和有限间接证据表明ABI筛查对未选择或无症状人群的获益,现有研究提示敏感性低且对健康结局无有益影响。
研究设计与样本
- 系统综述纳入5项研究(N=5864),评估ABI筛查PAD的间接证据,检索MEDLINE、PubMed和Cochrane图书馆2012年1月至2017年5月的英文文献。
主要发现
- 无基于人群的筛查试验评估单独ABI筛查的直接获益或危害。
- 一项诊断准确性研究(n=306)显示ABI筛查敏感性低(7%-34%)、特异性高(96%-100%)。
- 两项试验(n=4626)显示阿司匹林(每日100 mg)对复合心血管结局无显著影响(调整HR 1.00 [95% CI, 0.81-1.23] 和 HR 0.98 [95% CI, 0.76-1.26])。
- 一项试验(n=3350)显示阿司匹林未显著增加大出血事件(调整HR 1.71 [95% CI, 0.99-2.97])或大胃肠出血(RR 1.13 [95% CI, 0.44-2.91])。
- 两项运动试验(n=932)报告12周和52周时生活质量、步行障碍问卷步行距离或症状无差异,未报告危害。
关键数值与推荐
- ABI筛查诊断PAD的敏感性为7%-34%,特异性为96%-100%。
- 阿司匹林对复合心血管结局的调整HR为1.00(95% CI, 0.81-1.23)和0.98(95% CI, 0.76-1.26)。
- 阿司匹林对大出血事件的调整HR为1.71(95% CI, 0.99-2.97),大胃肠出血RR为1.13(95% CI, 0.44-2.91)。
临床怎么用
- 当前证据不支持对无症状人群进行ABI筛查以改善健康结局。
- 对筛查发现的无症状PAD患者,阿司匹林治疗未显示显著心血管获益。
局限性
- 缺乏直接评估ABI筛查获益或危害的随机对照试验。
- 现有研究存在重要局限性,间接证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Peripheral artery disease (PAD) is associated with a high risk for cardiovascular events and poor ambulatory function, even in the absence of symptoms. Screening for PAD with the ankle-brachial index (ABI) may identify patients in need of treatment to improve health outcomes. OBJECTIVE: To systematically review evidence for the US Preventive Services Task Force on PAD screening with the ABI, the diagnostic accuracy of the test, and the benefits and harms of treatment of screen-detected PAD. DATA SOURCES: MEDLINE, PubMed, and the Cochrane Central Register of Controlled Trials for relevant English-language studies published between January 2012 and May 2, 2017. Surveillance continued through February 7, 2018. STUDY SELECTION: Studies of unselected or generally asymptomatic adults with no known cardiovascular disease. DATA EXTRACTION AND SYNTHESIS: Independent critical appraisal and data abstraction by 2 reviewers. MAIN OUTCOMES AND MEASURES: Cardiovascular morbidity; PAD morbidity; mortality; health-related quality of life; diagnostic accuracy; and serious adverse events. RESULTS: Five studies (N = 5864 participants) were included that examined the indirect evidence for the benefits and harms of screening and treatment of screen-detected PAD. No population-based screening trials evaluated the direct benefits or harms of PAD screening with the ABI alone. A single diagnostic accuracy study of the ABI compared with magnetic resonance angiography gold-standard imaging (n = 306) found low sensitivity (7%-34%) and high specificity (96%-100%) in a screening population. Two adequately powered trials (n = 4626) in asymptomatic populations with and without diabetes with a variably defined low ABI (≤0.95 or ≤0.99) showed no statistically significant effect of aspirin (100 mg daily) for composite CVD outcomes (adjusted hazard ratio [HR], 1.00 [95% CI, 0.81-1.23] and HR, 0.98 [95% CI, 0.76-1.26]). One trial (n = 3350) demonstrated no statistically significant increase in major bleeding events with the use of aspirin (adjusted HR, 1.71 [95% CI, 0.99- 2.97]) and no statistically significant increase in major gastrointestinal bleeding (relative risk, 1.13 [95% CI, 0.44-2.91]). Two exercise trials (n = 932) in screen-relevant populations reported no differences in quality of life, Walking Impairment Questionnaire walking distance, or symptoms at 12 and 52 weeks; no harms were reported. CONCLUSIONS AND RELEVANCE: There was no direct evidence and limited indirect evidence on the benefits of PAD screening with the ABI in unselected or asymptomatic populations. Available studies suggest low sensitivity and lack of beneficial effect on health outcomes, but these studies have important limitations.
引用
- Guirguis-Blake JM, Evans CV, Redmond N, et al. Screening for Peripheral Artery Disease Using the Ankle-Brachial Index: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2018. PMID: 29998343. doi:10.1001/jama.2018.4250
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。